Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-17, Stock:JNJ, The news for the past five days is as follows:
2018-07-10: NEWS1: Dow ETF in Focus Ahead of Q2 Earnings.NEWS2: Dow ETF in Focus Ahead of Q2 Earnings.NEWS3: See Which Of The Latest 13F Filers Holds Johnson & Johnson.NEWS4: See Which Of The Latest 13F Filers Holds Johnson & Johnson.NEWS5: JNJ’s Vision Care Segment Witnessed Solid Growth in Q1 2018.NEWS6: A Performance Overview of JNJ’s Surgical Medical Devices Business.NEWS7: How Is Johnson & Johnson’s Orthopedics Business Positioned?.
2018-07-11: NEWS1: Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2.NEWS2: Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2.NEWS3: Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2018.NEWS4: Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2018.NEWS5: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018.NEWS6: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018.NEWS7: Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares.NEWS8: Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline.
2018-07-12: NEWS1: Johnson & Johnson's Official Statement in Response to Today's Verdict in St. Louis Trial.NEWS2: Nearly $4.7 billion awarded in baby powder lawsuit.NEWS3: St. Louis Jury Returns $4.69 Billion Verdict in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer.NEWS4: Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case.NEWS5: The Latest: Jury awards nearly $4.7 billion in powder case.NEWS6: Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case.NEWS7: J&J Ordered to Pay $4.14 Billion Punitive Damages.NEWS8: $550 million awarded in lawsuit linking cancer, baby powder.NEWS9: Cramer: Most market-watchers are wrong. Stocks just aren't that expensive.NEWS10: REPLAY: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth.NEWS11: Jury orders J&J to pay $550 mln in Missouri asbestos cancer case.NEWS12: J&J Ordered To Pay $4.69 Bln In Baby Powder Case.NEWS13: J&J Ordered To Pay $4.69 Bln In Baby Powder Case.NEWS14: Why Johnson & Johnson Stock Has Lost 13% So Far in 2018.NEWS15: Why Johnson & Johnson Stock Has Lost 13% So Far in 2018.NEWS16: Markets Right Now: Tech gains push Nasdaq to all-time high.NEWS17: J&J Ordered to Pay $550 Million in Talc Asbestos Cancer Case.NEWS18: Drug Makers Can't Cure Investor Impatience.NEWS19: Why Johnson & Johnson Stock Has Lost 13% So Far in 2018.NEWS20: Bank Earnings: JPMorgan, Wells Fargo And Citigroup Are Slated To Report Friday Morning.NEWS21: Johnson & Johnson's Breakout May Boost Stock 11%.NEWS22: Two Dow stocks to buy and one to fade in a volatile market.NEWS23: Pfizer (PFE) to Reorganize Business Into Three New Units.NEWS24: Pfizer (PFE) to Reorganize Business Into Three New Units.NEWS25: AbbVie's Imbruvica Fails in Phase III Blood Cancer Study.NEWS26: AbbVie's Imbruvica Fails in Phase III Blood Cancer Study.NEWS27: Markets Right Now: Technology stocks lead US rebound.NEWS28: Video: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth.NEWS29: Why Jim Cramer Is Bullish on Johnson & Johnson Shares.NEWS30: Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings.NEWS31: What Analysts Think of Endo International.NEWS32: J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What&apos;s Up?.
2018-07-13: NEWS1: Johnson & Johnson Ordered to Pay $4.69 Billion in Cancer Case.NEWS2: The Johnson & Johnson Talc Lawsuit Isn’t Over Yet.NEWS3: The Johnson & Johnson Talc Lawsuit Isn’t Over Yet.NEWS4: Why Johnson & Johnson, Cisco Systems, and Ingredion Slumped Today.NEWS5: Why Johnson & Johnson, Cisco Systems, and Ingredion Slumped Today.NEWS6: Jim Cramer: This Market Isn't Done Going Higher.NEWS7: Johnson & Johnson still battling thousands of cases involving its baby powder.NEWS8: Why Johnson & Johnson, Cisco Systems, and Ingredion Slumped Today.NEWS9: Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict.NEWS10: Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict.NEWS11: Wells Fargo and AT&T slide while Walmart and Terex climb.NEWS12: Correction: Talc Powder-Cancer Lawsuit story.NEWS13: US STOCKS-S&P 500 at five-month high, but banks weigh after results.NEWS14: J&J vows to overturn $4.7 billion talc verdict but experts see hurdles.NEWS15: Despite some wobbles, stocks end the week with more gains.NEWS16: Health Care Sector Update for 07/13/2018: PFE,RCUS,NVRO,ISRG,JNJ.NEWS17: Health Care Sector Update for 07/13/2018: PFE,RCUS,NVRO,ISRG,JNJ.NEWS18: J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit.NEWS19: J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit.NEWS20: Stocks End Slightly Higher; Indexes Post Gains For Week.NEWS21: J&J to pay $4.7 bln in cancer case.NEWS22: US STOCKS-S&P 500 at five-month high, but banks weigh after results.NEWS23: Stocks Hold Onto Slim Gains in Final Hour.NEWS24: Noteworthy Friday Option Activity: JNJ, JBHT, EXPE.NEWS25: Noteworthy Friday Option Activity: JNJ, JBHT, EXPE.NEWS26: The Johnson & Johnson Talc Lawsuit Isn’t Over Yet.NEWS27: Johnson & Johnson ordered to pay $4.7 billion in talcum p....NEWS28: Health Care Sector Update for 07/13/2018: NVRO,ISRG,JNJ,RCUS,PODD.NEWS29: Health Care Sector Update for 07/13/2018: NVRO,ISRG,JNJ,RCUS,PODD.NEWS30: Johnson & Johnson’s Q2 2018 Earnings Estimates.NEWS31: Will Johnson & Johnson Meet Sales Estimates for Q2 2018?.NEWS32: Johnson & Johnson: The Word on Wall Street ahead of Q2 Earnings.NEWS33: Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug.NEWS34: Stocks shuffle toward another weekly gain as oil prices rise.NEWS35: J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit.NEWS36: J&J's $4.69 Billion Talc Verdict May Open Floodgates to Suits.NEWS37: Dow Trades Higher After Big U.S. Banks Post Mixed Earnings.NEWS38: Jury Awards Nearly $4.7 Billion In Powder Case.NEWS39: The Midday Rundown: July 13, 2018.NEWS40: Industrial and energy companies lift US stocks; banks slip.NEWS41: J&J Shares Slip as Investors Assess Loss From Talc Legal Saga.NEWS42: The Late Morning Rundown: July 13, 2018.NEWS43: US STOCKS-S&P hits 5-month high as industrials, energy boost; banks weigh.NEWS44: Why Johnson & Johnson Was Down 2% This Morning.NEWS45: Updated: J&J Slumps on $4.7 Billion Award to Cancer Patients.NEWS46: Stocks Finish Lackluster Session Modestly Higher - U.S. Commentary.NEWS47: Stocks Finish Lackluster Session Modestly Higher - U.S. Commentary.NEWS48: US STOCKS-Industrials, energy push S&P to 5-month high; banks weigh.NEWS49: Better Buy: Amgen Inc. vs. Johnson & Johnson.NEWS50: Better Buy: Amgen Inc. vs. Johnson & Johnson.NEWS51: Johnson & Johnson Posting Notable Loss But Well Off Lows.NEWS52: Johnson & Johnson Posting Notable Loss But Well Off Lows.NEWS53: Stocks - Wells Fargo, Johnson & Johnson, AT&T Slump in Pre-market, JP Morgan gains.NEWS54: 2 Dow Stocks for a Volatile Market.NEWS55: Johnson & Johnson -- Moody's: Talc award against J&J is credit negative.NEWS56: The Top 5 Johnson & Johnson Shareholders (JNJ).NEWS57: [video]Dow Makes Move Higher After Big U.S. Banks Post Mixed Earnings.NEWS58: US STOCKS-Wall Street flat as industrials offset slide in bank stocks.NEWS59: Better Buy: Amgen Inc. vs. Johnson & Johnson.NEWS60: JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?.NEWS61: JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?.NEWS62: Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit.NEWS63: Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit.NEWS64: Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?.NEWS65: Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?.NEWS66: Attorney: J&J won't be 'intimidated' into removing talc products after $4.7 billion cancer case damages.NEWS67: Shaky results from Wells Fargo and other banks hit US stocks.NEWS68: Morning Movers: AT&T Sinks, JPMorgan Jumps, J&J Slides.NEWS69: Morning Movers: AT&T Sinks, JPMorgan Jumps, J&J Slides.NEWS70: J&J Ordered to Pay $4.14 Billion Punitive Damages.NEWS71: J&J Slumps on $4.7 Billion Award to Cancer Patients.NEWS72: Stocks Slip as Big U.S. Banks Post Mixed Earnings.NEWS73: Jury Returns $4.7B Verdict Against Johnson & Johnson In Asbestos-Laced Talcum Case.NEWS74: Johnson & Johnson Tumbles After $4.7 Billion Baby Powder-Cancer Link Verdict.NEWS75: US STOCKS-Futures flat as Wall St banks report mixed results.NEWS76: Morning Movers: AT&T Sinks, JPMorgan Jumps, J&J Slides.NEWS77: Will J&J&apos;s (JNJ) Pharma Segment Strength Drive Q2 Earnings?.NEWS78: Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit.NEWS79: Health Care Sector Update for 07/13/2018: JNJ,RCUS,PODD.NEWS80: Health Care Sector Update for 07/13/2018: JNJ,RCUS,PODD.NEWS81: JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?.NEWS82: Johnson & Johnson ordered to pay $4.7 billion in talc pow....NEWS83: The Market In 5 Minutes: AT&T-Time Warner Appeal, Johnson & Johnson Lawsuit, Theresa May And More.NEWS84: JPMorgan, AT&T-Time Warner, J&J, Apple and Blue Origin - 5 Things You Must Know.NEWS85: Today's Research Reports on Trending Tickers: Johnson & Johnson and AstraZeneca.NEWS86: US STOCKS-Futures flat as JP Morgan kicks off earnings season.NEWS87: Stocks making the biggest moves premarket: JPM, DIS, BLK, T, JNJ, MCD & more.NEWS88: Johnson & Johnson vows to appeal $4.7 billion talcum products verdict.NEWS89: [video]JPMorgan, AT&T-Time Warner, J&J, Apple and Blue Origin - 5 Things You Must Know.NEWS90: Johnson & Johnson ordered to pay record $4.7bn damages over talc cancer lawsuit.NEWS91: J&J hit with $4.7B verdict in talcum powder case.NEWS92: Does J&J’s Baby Powder Cause Cancer? A Jury Just Said Yes With an Enormous $4.69 Billion Penalty.NEWS93: PRESS DIGEST -Wall Street Journal - July 13.NEWS94: Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case.NEWS95: [$$] J&J Hit With $4.7 Billion Jury Verdict in Baby Powder Suit.NEWS96: Johnson & Johnson Hit by $4.7 Billion Jury Verdict in Ovarian Cancer Case.
2018-07-16: NEWS1: Day Ahead: Top 3 Things to Watch.NEWS2: Johnson & Johnson (JNJ) Slips 1.1% Ahead of Earnings: What To Watch.NEWS3: Johnson & Johnson (JNJ) Slips 1.1% Ahead of Earnings: What To Watch.NEWS4: Pacira Focused on Exparel Development Amid Competition.NEWS5: Pacira Focused on Exparel Development Amid Competition.NEWS6: Thai Shares May See Continued Selling Pressure.NEWS7: Thai Shares May See Continued Selling Pressure.NEWS8: Indonesia Bourse May Extend Monday's Losses.NEWS9: Indonesia Bourse May Extend Monday's Losses.NEWS10: Pacira Focused on Exparel Development Amid Competition.NEWS11: Johnson & Johnson Q2 Earnings Preview.NEWS12: Hong Kong Bourse Due For Profit Taking.NEWS13: Hong Kong Bourse Due For Profit Taking.NEWS14: Johnson & Johnson (JNJ) Slips 1.1% Ahead of Earnings: What To Watch.NEWS15: Losing Streak May Continue For China Stock Market.NEWS16: Losing Streak May Continue For China Stock Market.NEWS17: Taiwan Shares May Open Under Pressure.NEWS18: Taiwan Shares May Open Under Pressure.NEWS19: Pre-Market Earnings Report for July 17, 2018 :  JNJ, UNH, GS, SCHW, PLD, PGR, OMC, CMA, FHN, NEOG, NSM, MBWM.NEWS20: Pre-Market Earnings Report for July 17, 2018 :  JNJ, UNH, GS, SCHW, PLD, PGR, OMC, CMA, FHN, NEOG, NSM, MBWM.NEWS21: Losses May Accelerate For Singapore Stock Market.NEWS22: Losses May Accelerate For Singapore Stock Market.NEWS23: 10 Dow Jones Titans to Buy Now.NEWS24: Malaysia Bourse Overdue For Downside Correction.NEWS25: Malaysia Bourse Overdue For Downside Correction.NEWS26: Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?.NEWS27: Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?.NEWS28: South Korea Shares May Take Further Damage.NEWS29: South Korea Shares May Take Further Damage.NEWS30: Johnson & Johnson earnings: Time to talk about drug prices.NEWS31: Daily Dividend Report: SJM, NNN, CPG, JNJ, PEP.NEWS32: Daily Dividend Report: SJM, NNN, CPG, JNJ, PEP.NEWS33: J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay.NEWS34: J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay.NEWS35: Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?.NEWS36: Major Averages Close Mixed Following Lackluster Session - U.S. Commentary.NEWS37: Major Averages Close Mixed Following Lackluster Session - U.S. Commentary.NEWS38: Company News For Jul 16, 2018.NEWS39: Company News For Jul 16, 2018.NEWS40: Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018.NEWS41: J&J&apos;s (JNJ) Invokana Label Expansion Filing Hit by FDA Delay.NEWS42: What to Expect from J&J’s Consumer Business in Q2 2018.NEWS43: Earnings Preview: Healthcare Giant Johnson & Johnson Set To Report Tuesday Morning.NEWS44: The World Cup of Dividend Stocks: 8 of the Most Dependable Dividends.NEWS45: The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft.NEWS46: The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft.NEWS47: Add Up The Parts: DIVB Could Be Worth $29.NEWS48: Add Up The Parts: DIVB Could Be Worth $29.NEWS49: 5 Top Stock Trades for Monday — Buy Netflix Ahead of Earnings?.NEWS50: 5 Top Stock Trades for Monday — Buy Netflix Ahead of Earnings?.NEWS51: Company News For Jul 16, 2018.NEWS52: Round Two Of Bank Earnings Coming Up With Bank of America, Goldman Sachs And Morgan Stanley.NEWS53: Will Pharmaceuticals Keep Fueling J&J’s Performance in Q2 2018?.NEWS54: Stocks Continue To Experience Choppy Trading - U.S. Commentary.NEWS55: Stocks Continue To Experience Choppy Trading - U.S. Commentary.NEWS56: Today's Research Reports on Stocks to Watch: Biocept and Johnson and Johnson.NEWS57: The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft.NEWS58: Johnson & Johnson: Increase in Operating Margin in Q2 2018?.NEWS59: Stocks Turning In Lackluster Performance In Morning Trading - U.S. Commentary.NEWS60: Stocks Turning In Lackluster Performance In Morning Trading - U.S. Commentary.NEWS61: 5 Top Stock Trades for Monday — Buy Netflix Ahead of Earnings?.NEWS62: Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary.NEWS63: Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary.

Answer: Rise